Change in Cardiometabolic Health Following Participation in Cardiac Rehabilitation for Coronary Heart Disease: Effect Modification by Metabolic Syndrome Status
Joshua Garfein,Elizabeth Gnatiuk,Eric Brandt,Chih-Wen Pai,Joseph Bryant,Eva Kline-Rogers,Samantha Fink,Melvyn Rubenfire
DOI: https://doi.org/10.2147/dmso.s470120
2024-11-28
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Joshua Garfein, 1 Elizabeth A Gnatiuk, 1, 2 Eric J Brandt, 1, 3 Chih-Wen Pai, 1 Joseph Bryant, 1 Eva Kline-Rogers, 1 Samantha Fink, 1 Melvyn Rubenfire 1 1 Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; 2 Experimental Medicine Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 3 Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA Correspondence: Melvyn Rubenfire, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, 24 Frank Lloyd Wright Dr, Lobby A., Ann Arbor, MI, 48106-0363, USA, Tel +1 734 998 7411, Fax +1 734 998 7456, Email Objective: To investigate changes in cardiometabolic risk factors after completion of cardiac rehabilitation (CR) for coronary heart disease (CHD) and ascertain whether the magnitude of improvement in cardiometabolic health differs between those with and without metabolic syndrome (MetS). Methods: In this observational cohort study, data were analyzed from 1984 patients enrolled in CR at the University of Michigan between 2011-01-01 and 2020-02-29 for the indication of CHD. Patient characteristics were collected from standardized health questionnaires and during CR intake evaluations. Cardiometabolic biomarkers were recorded from baseline laboratory data and re-examined upon completion of CR. Differences in baseline patient characteristics by MetS status were compared using chi-square tests. Wilcoxon rank-sum tests were used to compare baseline differences, and signed-rank tests were used to evaluate the change in variables between baseline and completion of CR. The difference of change by MetS status was assessed using difference-in-differences regression models. Results: Of the 1984 patients, 1070 (53.9%) met the criteria for MetS at baseline, of which 770 were male (72.0%). Those with MetS lost 1.43 pounds more (95% CI: 0.56, 2.31, P = 0.001), experienced a 0.21 larger drop in body mass index (95% CI: 0.03, 0.37, P = 0.02), and had a 0.31 greater reduction in waist circumference (95% CI: 0.08, 0.54, P = 0.008). Difference-in-differences regression models revealed those with MetS experienced a greater reduction in triglycerides and fasting glucose, with a difference of change of − 8.70 for triglycerides (95% CI: − 15.04, − 2.37, P = 0.007) and − 5.48 for glucose (95% CI: − 10.44, − 0.53, P = 0.03). There was no significant difference in the change in HDL-C or LDL-C for MetS status. Conclusion: Compared to those without MetS, patients with MetS experienced a comparable or greater benefit from CR, particularly with respect to improvements in MetS components. Keywords: chronic disease management, coronary heart disease, cardiometabolic risk factors, cardiovascular disease Metabolic syndrome (MetS) is characterized by a clustering of risk factors for cardiovascular disease (CVD) and diabetes mellitus (DM). 1–3 Criteria for the clinical diagnosis of MetS commonly include the presence of at least three of the following five factors: abdominal obesity, elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, hypertension and impaired fasting blood glucose. 4,5 The overlapping of these conditions contribute substantially to morbidity and mortality, particularly due to increased risk of DM 1 and CVDs such as coronary heart disease (CHD), heart failure (HF), and stroke. 2,6 Cardiac rehabilitation (CR) is a comprehensive, evidence-based program designed primarily for secondary prevention of CVD. Robust literature supports the use of CR as a cost-effective intervention for individuals with a variety of cardiovascular conditions, with associated improvements in quality of life, morbidity, and mortality. 3 Available evidence suggests that CR improves MetS, including each of its components. 7 Previous research has indicated that it may be intrinsic factors, such as age, sex, or body mass index (BMI) that determine the level of functional improvement in patients undergoing CR, 8 and other studies have found that CR is associated with smaller improvements in cardiometabolic health among those with DM (particularly type II) than among those without. 9,10 However, whether MetS modifies the impact of CR on cardiometabolic health remains unclear. In this study, we investigated changes in cardiometabolic risk factors from before to after the completion of CR in individuals with CHD and compared these changes amongst those with or without MetS identified at baseline. We hypot -Abstract Truncated-
endocrinology & metabolism